Why?
1. APIs are becoming more and more potent. According to an estimation by ISPE (Winter Conference Berlin 2002), by 2010 more than 85 % of all NCE will be classified potent (OEL < 10 µg/m³). 2. Health and safety authorities all around the world are putting more focus on the protection of operators dealing with these substances. 3. Suppliers of various hardware components have developed a huge variety of containment solutions, making it difficult to decide on the optimal solution, even for experienced people.
A NEW article from Dr. Harald Stahl
Dr Harald Stahl is a Senior Pharmaceutical Technologist with GEA Pharma Systems. He is an executive member of the ISPE Containment Community of Practice (CCOP), and has published more than 20 papers on various aspects of solid dosage form production, of which several have a special focus on containment aspects. Dr Stahl holds a Diploma in Physics and a PhD in Chemical Engineering.
To read the complete article, click on this link
Contact:
Dr Harald Stahl
Senior pharmaceutical technologist at
GEA Pharma Systems
Tel. +49 6349 927 706
Email: harald.stahl@geagroup.com
Press Contact:
Kris De Baere
Marketing Manager
GEA Pharma Systems
Office: +32 (0) 3 350 12 41, Mobile: + 32 (0) 473 73 19 45
Email: kris.debaere@geagroup.com